Vericel (VCEL) Assets (2010 - 2026)
Vericel (VCEL) posted Assets of $502.9 million for Q2 2026, up 3.55% sequentially from $485.6 million in Q1 2026, and up 15.44% YoY from $435.6 million in Q2 2025.
Vericel (VCEL) Assets (2010 - 2026) Analysis & Trends
Vericel has reported Assets for 17 years, with the latest figure at $502.9 million in Q2 2026.
- Quarterly Assets rose 15.44% year-over-year to $502.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $502.9 million (up 15.44% YoY) and the FY2025 annual result came in at $488.0 million, up 12.77% from the prior year.
- Assets rose to $502.9 million in Q2 2026 per VCEL's latest filing, from $485.6 million in the prior quarter.
- Over five years, Assets peaked at $502.9 million in Q2 2026 and troughed at $240.3 million in Q1 2022.
- A 5-year average of $366.7 million and a median of $366.8 million in 2024 frame the typical range for Assets.
- The sharpest annual moves came in 2022 and 2024: Assets increased 10.3% in 2022, then soared 34.54% in 2024.
- Over 5 years, Assets stood at $273.0 million in 2022, then gained by 29.54% to $353.7 million in 2023, then advanced by 22.36% to $432.7 million in 2024, then climbed by 12.77% to $488.0 million in 2025, then rose by 3.05% to $502.9 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $502.9 million, $485.6 million, and $488.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 502.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 502.87 Mn |
| Mar 31, 2026 | 485.63 Mn |
| Dec 31, 2025 | 487.97 Mn |
| Sep 30, 2025 | 453.27 Mn |
| Jun 30, 2025 | 435.61 Mn |
| Mar 31, 2025 | 424.59 Mn |
| Dec 31, 2024 | 432.72 Mn |
| Sep 30, 2024 | 390.41 Mn |
| Jun 30, 2024 | 376.84 Mn |
| Mar 31, 2024 | 356.66 Mn |
| Dec 31, 2023 | 353.66 Mn |
| Sep 30, 2023 | 318.13 Mn |
| Jun 30, 2023 | 310.71 Mn |
| Mar 31, 2023 | 265.10 Mn |
| Dec 31, 2022 | 273.00 Mn |
| Sep 30, 2022 | 248.02 Mn |
| Jun 30, 2022 | 244.82 Mn |
| Mar 31, 2022 | 240.29 Mn |
| Dec 31, 2021 | 243.71 Mn |
| Sep 30, 2021 | 224.14 Mn |